Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04689711 · ClinicalTrials.gov registry record
Prognostic Models for COVID-19 Care
A clinical trial of COVID-19, sponsored by Tufts Medical Center.
- Completed
- Registry status
- 21
- Enrollment target
- 2
- Study locations
NCT04689711: Completed study of COVID-19, sponsored by Tufts Medical Center.
NCT04689711 is a study of COVID-19 that has completed, run by Tufts Medical Center. The registered enrollment target is 21 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04689711, a study of COVID-19, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
Approximately 20% of patients hospitalized with COVID-19 require intensive care and possibly invasive mechanical ventilation (MV). Patient preferences with COVID-19 for MV may be different, because intubation for these patients is often prolonged (for several weeks), is administered in settings characterized by social isolation and is associated with very high average mortality rates. Supporting patients facing this decision requires providing an accurate forecast of their likely outcomes based on their individual characteristics. The investigators therefore aim to: 1. Develop 3 CPMs in each of 2 hospital systems (i.e., 6 distinct models) to predict: i) the need for MV in patients hospitalized with COVID-19; ii) mortality in patients receiving MV; iii) length of stay in the ICU. 2. Evaluate the geographic and temporal transportability of these models and examine updating approaches. 1. To evaluate geographic transportability, the investigators will apply the evaluation and updating framework developed (in the parent PCORI grant) to assess CPM validity and generalizability across the different datasets. 2. To evaluate temporal transportability, the investigators will examine both the main effect of calendar time and also examine calendar time as an effect modifier. 3. Engage stakeholders to facilitate best use of these CPMs in the care of patients with COVID-19.
Primary Outcome
Aim 1 Outcome: Changes in Area under receiver operating characteristic curve (AUC) \[delta AUC\] for models predicting the probability of: the need for MV in patients hospitalized with COVID-19.
Conditions Studied
Study Locations (2)
Massachusetts
- Tufts Medical Center - Boston
New York
- Northwell Health (The Feinstein Institutes for Medical Research) - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2021-08-31 |
What the finished NCT04689711 record still lists
NCT04689711 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04689711 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04689711 about?
NCT04689711 is a clinical study titled "Prognostic Models for COVID-19 Care". Approximately 20% of patients hospitalized with COVID-19 require intensive care and possibly invasive mechanical ventilation (MV). Patient preferences with COVID-19 for MV may be different, because intubation for these patients is often prolonged (for several weeks), is administered in settings char...
What is the current status of trial NCT04689711?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2020-12-07. Estimated completion is 2021-08-31.
What conditions does trial NCT04689711 study?
This clinical trial studies the following conditions: COVID-19.
Who is sponsoring clinical trial NCT04689711?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04689711 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04689711's enrollment target sits among peer trials
21 277th of 298 higher than 21 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI